Vesalio announces oversubscribed Class A financing
Vesalio, an emerging leader in improving outcomes in patients with vascular occlusion, is proud to announce it has oversubscribed its Class A financing round.
Vesalio Announces Completion of Enrollment in its FDA Enabling Stroke Study
Vesalio announces the completion of enrollment in its FDA IDE clinical study for acute ischemic stroke.
Vesalio Announces Earl Slee as New Board Observer and Senior Advisor to the Company
As a board observer and senior advisor to the company, Earl Slee brings extensive medical device innovation and business development expertise.
Vesalio Announces Appointment of Mike Kujak as its New Independent Board Chairman
As an independent board chairman, Mike Kujak will bring expert knowledge and know-how from his years of leadership in the medical device start-up space.
Vesalio Initiates Clinical Study Evaluating Innovative Thrombectomy Technique for Patients with STEMI
Vesalio announced the start of enrollment in its NATURE study using enVast™, the company’s first thrombectomy system for patients presenting with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention.
Vesalio Secures Class A Funding
Vesalio announces it has successfully secured a Class A financing round. The proceeds will be utilized to support the ongoing US IDE stroke study, establish US infrastructure, expand its innovative product portfolio, and scale international business.
Vesalio Initiates FDA IDE Stroke Study
Vesalio announces another key milestone to support entry into the US neurovascular thrombectomy market. Enrollment has commenced in the Vesalio CLEAR acute ischemic stroke FDA IDE clinical trial utilizing the NeVaTM thrombectomy technology platform.
Vesalio Attains Key FDA Clinical Study Milestone
Vesalio announces it has accomplished a key FDA IDE study milestone to support entry into the US neurovascular market. Enrollment in the VITAL 1 clinical trial, assessing the company’s NeVa VS™ technology in the treatment of symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH), has been completed.
Vesalio Receives Peripheral FDA 510k Clearance and Additional CE Approval
Vesalio reports it has obtained an FDA 510k clearance and its 4th CE approval. The FDA 510k indication is for the removal of thrombi in peripheral blood vessels.
Initiates Virtual Training and Announces Pass Effect Rate Publication
Vesalio announces it has executed additional exclusive distribution agreements in Europe, Latin America, Asia, and the Middle East. With these new partnerships, the NeVa™ Thrombectomy System has gained market coverage in 53 countries.
